Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2018 · 10-Q
Revenue$52.93K$52.93K−81.7% vs Q1 2017 Net Income-$432.14K-$432.14KN/M vs Q1 2017 EPS Diluted-$0.02-$0.02N/M vs Q1 2017 Operating Income-$396,269N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Free Cash Flowderived-$525,784N/M Margins · derivedOperating margin-748.7%−638.2 pt vs Q1 2017
Net margin-816.5%−683.5 pt vs Q1 2017
ended Jun 30, 2017 · filed Aug 18, 2017 · 49 d after period end